Business Context and Reporting Period
Company: Health In Tech, Inc. (Nasdaq: HIT)
Filing Type: Form 8-K (Current Report)
Date of Report: March 25, 2026
Reporting Period: Event-based (March 25, 2026)
Business Context: The Company, an emerging growth company incorporated in Nevada, announced the entry into a Private Investment in Public Equity (PIPE) financing transaction.
Key Financial Metrics
Capital Raise: The Company entered into a securities purchase agreement to sell 5,600,000 shares of Class A Common Stock.
Gross Proceeds: Approximately $7.0 million (before deducting placement agent fees and offering expenses).
Use of Proceeds: Expansion of sales distribution, technology development, new product development, general corporate purposes, and working capital.
Transaction Status: Expected to close on or about March 27, 2026, subject to customary closing conditions.
Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity ratios.
Material Changes
This filing reports a material definitive agreement and unregistered sales of equity securities rather than operational performance changes. The primary material change is the agreement to issue 5,600,000 new shares to accredited investors, which will result in dilution to existing shareholders upon closing. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
- Management Commentary: Management intends to utilize net proceeds to advance technology and product development and support working capital needs.
- Registration Rights: The Company must file a resale registration statement within 30 days of the agreement and use commercially reasonable efforts to have it declared effective.
- Lock-Up Agreements: Directors and officers are subject to customary lock-up agreements for 60 days after the effectiveness of the resale registration statement.
- Risks and Contingencies: The transaction is subject to customary closing conditions. The filing includes standard forward-looking statement disclaimers regarding uncertainties in operational results, financial condition, and market opportunities. The Company undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $7.0 million gross proceeds.
- Review the definitive Placement Agency Agreement (Exhibit 10.3) to determine the exact placement fee and expenses to calculate net proceeds.
- Monitor the filing of the resale registration statement (Form S-1 or S-3) within the required 30-day window.
- Assess the dilution impact of the 5,600,000 new shares on existing ownership percentages.
- Confirm the specific allocation of funds between sales expansion, technology development, and working capital in future reports.